{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/97581"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/97581","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Expression and regulation of the rate-limiting enzymes of the kynurenine pathway in the mouse brain","abstract":"During the mid-1900’s, early anti-depressants were developed to increase levels of catecholamines within the brain, leading to the theory that depression symptomology was a result of an imbalance of neurotransmitters within the brain. To date, the catecholamine theory of depression is still held to be the prevailing theory as selective serotonin reuptake inhibitors being the most commonly prescribed anti-depressants. However, the incidence of depression is still rising with a vast amount of patients failing to respond to current treatments, and with this knowledge, additional theories of the neurobiology of depression have arisen over the past 30 years. A leading theory is Kynurenine Pathway activation in relation to inflammation- or stress-induced depression-like behaviors. There has been a tremendous amount of data connecting activated immune system (or hypothalamic-pituitary-adrenal axis), increased kynurenine production and depression symptomology. Thus, understanding the factors that activate this pathway, as well as determining a relationship between anti-depressants and regulation of the Kynurenine Pathway, is an important next step in understanding the complex etiology of depression. My work has focused on 1) describing interactions between inflammation and stress to accentuate the expression of rate-limiting enzymes (indoleamine/tryptophan-2,3-dioxygenase: DOs) that metabolize the essential amino acid tryptophan to kynurenine, 2) detailing a novel interaction between galectins and interferon-gamma to accentuate DO expression within the brain, and finally 3) discuss the ability of current anti-depressant desipramine to block these interactions and attenuate DO expression within the brain and periphery as a possible new mechanism by which anti-depressants may be working to reduce depression symptomology.","abstract_html":"During the mid-1900’s, early anti-depressants were developed to increase levels of catecholamines within the brain, leading to the theory that depression symptomology was a result of an imbalance of neurotransmitters within the brain. To date, the catecholamine theory of depression is still held to be the prevailing theory as selective serotonin reuptake inhibitors being the most commonly prescribed anti-depressants. However, the incidence of depression is still rising with a vast amount of patients failing to respond to current treatments, and with this knowledge, additional theories of the neurobiology of depression have arisen over the past 30 years. A leading theory is Kynurenine Pathway activation in relation to inflammation- or stress-induced depression-like behaviors. There has been a tremendous amount of data connecting activated immune system (or hypothalamic-pituitary-adrenal axis), increased kynurenine production and depression symptomology. Thus, understanding the factors that activate this pathway, as well as determining a relationship between anti-depressants and regulation of the Kynurenine Pathway, is an important next step in understanding the complex etiology of depression. My work has focused on 1) describing interactions between inflammation and stress to accentuate the expression of rate-limiting enzymes (indoleamine/tryptophan-2,3-dioxygenase: DOs) that metabolize the essential amino acid tryptophan to kynurenine, 2) detailing a novel interaction between galectins and interferon-gamma to accentuate DO expression within the brain, and finally 3) discuss the ability of current anti-depressant desipramine to block these interactions and attenuate DO expression within the brain and periphery as a possible new mechanism by which anti-depressants may be working to reduce depression symptomology.","abstract_has_math":false,"creators":["Brooks, Alexandra Kelly"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Neuroscience","degree_department":null,"school":null,"contributors":["McCusker, Robert H.","Johnson, Rodney W.","Steelman, Andrew J.","Uddin, Eva M"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2017,"date_issued":"2017-08-10T19:52:02Z","date_published":"2017-08-10T19:52:02Z","updated_at":"2026-07-22T22:24:34Z","subjects":["Indoleamine","Kynurenine","Desipramine","Depression","Inflammation"],"languages":["en"],"rights":["Copyright 2017 Alexandra Brooks"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/97581","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["McCusker, Robert H.","Johnson, Rodney W.","Steelman, Andrew J.","Uddin, Eva M"]},{"key":"dc:creator","label":"Author","values":["Brooks, Alexandra Kelly"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2017-08-10T19:52:02Z","2019-08-11T09:15:32Z","2017-04-20","2017-05"]},{"key":"dc:type","label":"Dc Type","values":["text"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Neuroscience"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Indoleamine","Kynurenine","Desipramine","Depression","Inflammation"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2017 Alexandra Brooks"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/97581"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["During the mid-1900’s, early anti-depressants were developed to increase levels of catecholamines within the brain, leading to the theory that depression symptomology was a result of an imbalance of neurotransmitters within the brain. To date, the catecholamine theory of depression is still held to be the prevailing theory as selective serotonin reuptake inhibitors being the most commonly prescribed anti-depressants. However, the incidence of depression is still rising with a vast amount of patients failing to respond to current treatments, and with this knowledge, additional theories of the neurobiology of depression have arisen over the past 30 years. A leading theory is Kynurenine Pathway activation in relation to inflammation- or stress-induced depression-like behaviors. There has been a tremendous amount of data connecting activated immune system (or hypothalamic-pituitary-adrenal axis), increased kynurenine production and depression symptomology. Thus, understanding the factors that activate this pathway, as well as determining a relationship between anti-depressants and regulation of the Kynurenine Pathway, is an important next step in understanding the complex etiology of depression. My work has focused on 1) describing interactions between inflammation and stress to accentuate the expression of rate-limiting enzymes (indoleamine/tryptophan-2,3-dioxygenase: DOs) that metabolize the essential amino acid tryptophan to kynurenine, 2) detailing a novel interaction between galectins and interferon-gamma to accentuate DO expression within the brain, and finally 3) discuss the ability of current anti-depressant desipramine to block these interactions and attenuate DO expression within the brain and periphery as a possible new mechanism by which anti-depressants may be working to reduce depression symptomology.","Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2019-05-01","The student, Alexandra Brooks, accepted the attached license on 2017-04-19 at 15:21.","The student, Alexandra Brooks, submitted this Dissertation for approval on 2017-04-19 at 15:21.","This Dissertation was approved for publication on 2017-04-20 at 12:55.","DSpace SAF Submission Ingestion Package generated from Vireo submission #10802 on 2017-08-10 at 14:30:55","Made available in DSpace on 2017-08-10T19:52:02Z (GMT). No. of bitstreams: 2 BROOKS-DISSERTATION-2017.pdf: 5789986 bytes, checksum: 0593efd2c84e3934c6be70ba66c2ddbf (MD5) LICENSE.txt: 4213 bytes, checksum: cc27d72351bb97346c26c1da33253cc5 (MD5) Previous issue date: 2017-04-20","Embargo set by: Colleen Fallaw for item 102634 Lift date: 2019-08-10T21:25:30Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited Restriction Lifted for Item 102634 on 2019-08-11T09:15:32Z."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Expression and regulation of the rate-limiting enzymes of the kynurenine pathway in the mouse brain"]}]}],"canonical_facts":{"dc:contributor":["McCusker, Robert H.","Johnson, Rodney W.","Steelman, Andrew J.","Uddin, Eva M"],"dc:creator":["Brooks, Alexandra Kelly"],"dc:date":["2017-08-10T19:52:02Z","2019-08-11T09:15:32Z","2017-04-20","2017-05"],"dc:description":["During the mid-1900’s, early anti-depressants were developed to increase levels of catecholamines within the brain, leading to the theory that depression symptomology was a result of an imbalance of neurotransmitters within the brain. To date, the catecholamine theory of depression is still held to be the prevailing theory as selective serotonin reuptake inhibitors being the most commonly prescribed anti-depressants. However, the incidence of depression is still rising with a vast amount of patients failing to respond to current treatments, and with this knowledge, additional theories of the neurobiology of depression have arisen over the past 30 years. A leading theory is Kynurenine Pathway activation in relation to inflammation- or stress-induced depression-like behaviors. There has been a tremendous amount of data connecting activated immune system (or hypothalamic-pituitary-adrenal axis), increased kynurenine production and depression symptomology. Thus, understanding the factors that activate this pathway, as well as determining a relationship between anti-depressants and regulation of the Kynurenine Pathway, is an important next step in understanding the complex etiology of depression. My work has focused on 1) describing interactions between inflammation and stress to accentuate the expression of rate-limiting enzymes (indoleamine/tryptophan-2,3-dioxygenase: DOs) that metabolize the essential amino acid tryptophan to kynurenine, 2) detailing a novel interaction between galectins and interferon-gamma to accentuate DO expression within the brain, and finally 3) discuss the ability of current anti-depressant desipramine to block these interactions and attenuate DO expression within the brain and periphery as a possible new mechanism by which anti-depressants may be working to reduce depression symptomology.","Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2019-05-01","The student, Alexandra Brooks, accepted the attached license on 2017-04-19 at 15:21.","The student, Alexandra Brooks, submitted this Dissertation for approval on 2017-04-19 at 15:21.","This Dissertation was approved for publication on 2017-04-20 at 12:55.","DSpace SAF Submission Ingestion Package generated from Vireo submission #10802 on 2017-08-10 at 14:30:55","Made available in DSpace on 2017-08-10T19:52:02Z (GMT). No. of bitstreams: 2 BROOKS-DISSERTATION-2017.pdf: 5789986 bytes, checksum: 0593efd2c84e3934c6be70ba66c2ddbf (MD5) LICENSE.txt: 4213 bytes, checksum: cc27d72351bb97346c26c1da33253cc5 (MD5) Previous issue date: 2017-04-20","Embargo set by: Colleen Fallaw for item 102634 Lift date: 2019-08-10T21:25:30Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited Restriction Lifted for Item 102634 on 2019-08-11T09:15:32Z."],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/97581"],"dc:language":["en"],"dc:rights":["Copyright 2017 Alexandra Brooks"],"dc:subject":["Indoleamine","Kynurenine","Desipramine","Depression","Inflammation"],"dc:title":["Expression and regulation of the rate-limiting enzymes of the kynurenine pathway in the mouse brain"],"dc:type":["text"],"thesis:degree_discipline":["Neuroscience"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:34Z"}